EBOS Group schedules October 21 annual meeting for EBOS Group stock

Published on 10/20/2026 at 21:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EBOS Group reported AUD 13.5 billion revenue for fiscal 2026, up 9.9 percent. EBOS Group stock costs EUR 10.23 at Lang & Schwarz on October 20, 2026.

Annual meeting and earnings

EBOS Group will hold its annual meeting on October 21, 2026.
Fiscal 2026 revenue rose 9.9 percent to AUD 13.5 billion.
EBOS Group stock was trading at EUR 10.23 at Lang & Schwarz on October 20, 2026 at 9:12 p.m. CEST.
Underlying EBITDA increased 5.0 percent to AUD 614.0 million in fiscal 2026.

EBO, NZEBOE0001S6, Illustration mit AI erstellt.

EBOS Group (ISIN NZEBOE0001S6) will hold its annual meeting on October 21, 2026, giving shareholders a scheduled forum to question management after a difficult period. BusinessDesk reported the meeting date and said chief executive Adam Hall and chair Liz Coutts would update investors in Auckland. The stock was trading at EUR 10.23 at Lang & Schwarz on October 20, 2026 at 9:12 p.m. CEST.

Revenue growth outpaced profit growth

EBOS reported fiscal 2026 revenue of AUD 13.5 billion, a 9.9 percent increase from the previous year. Underlying earnings before interest, taxes, depreciation and amortization rose 5.0 percent to AUD 614.0 million, while underlying net profit fell 3.1 percent to AUD 250.0 million. Kurums attributed the profit pressure to higher depreciation from the distribution-center renewal program and increased interest costs.

Healthcare remains the earnings anchor

The healthcare division generated underlying earnings of AUD 516.0 million in fiscal 2026, up 3.0 percent from the previous year, while healthcare revenue reached AUD 12.6 billion. Animal Care supplied the faster growth rate, with earnings before interest, taxes, depreciation and amortization rising 12.0 percent to AUD 138.0 million. BusinessDesk also reported that EBOS spent AUD 121.0 million on eight acquisitions during fiscal 2026.

Valuation and the next date

EBOS had a market capitalization of NZD 4.2 billion as of October 20, 2026, with a price-to-earnings ratio of 15.17 and a dividend yield of 0.06 percent. Its 52-week range was NZD 18.45 to NZD 29.50. The annual meeting on October 21 is the next scheduled corporate date identified for investors.

What the meeting puts on the agenda

The meeting comes as investors assess whether the completed warehouse investment can support stronger cash generation. Fiscal 2027 underlying EBITDA guidance stands at AUD 635.0 million to AUD 655.0 million, while planned capital expenditure is AUD 100.0 million. That combination places execution, leverage and the returns from medical technology and Animal Care at the center of the investment case.

Stock position and investor context

EBOS is listed on the NZX and ASX and distributes healthcare, medical, pharmaceutical and animal-care products across Australasia. The company also operates the TerryWhite Chemmart pharmacy franchise and owns brands including Black Hawk and VitaPet. For investors, the key contrast is clear: fiscal 2026 revenue expanded 9.9 percent, but underlying net profit declined 3.1 percent as the group absorbed the cost of its infrastructure program.

Trading position

EBOS Group stock was trading at EUR 10.23 at Lang & Schwarz on October 20, 2026 at 9:12 p.m. CEST. The quote provides the latest euro market indication while the scheduled annual meeting gives investors the next company-specific date.

The further course of trading is shown by the continuously updated real-time quote of EBOS Group stock.